Study	Reason for exclusion
Angulo 2000	This is a case series. Twenty‐one primary sclerosing cholangitis patients received 9 mg budesonide orally each day for one year. Liver biochemistry was marginally better, but at a cost of marked bone loss.
Boberg 2003	A retrospective study of primary sclerosing cholangitis that were treated with corticosteroids. The authors compared responders with non‐responders to corticosteroids. They concluded that certain subgroups of patients that respond to corticosteroids may have improved long‐term survival.
Burgert 1984	This is a case series. Ten primary sclerosing cholangitis patients received at least six months prednisone therapy. The mean initial prednisone dosage was 39 mg/day, which was tapered to 23 mg/day by six months. Seven of ten patients showed improvement in liver biochemistry variables and liver histology. Three patients with pruritus had relief within one month.
Grijm 1986	A case series of 21 patients with primary sclerosing cholangitis that were treated with biliary lavage with prednisolone.
Lindor 1991	This is a case series. Twelve primary sclerosing cholangitis patients received a combination of low‐dose prednisone (10 mg/day) and colchicine (0.6 mg bid) for two years. Their course of disease was compared with that of a group of historical controls. At six and 12 months, there was significantly more improvement in liver test results over baseline values in the patients receiving prednisone and colchicine than in the untreated controls. At 24 months, however, no significant differences in biochemical tests were observed between the treated and untreated patients.
Schramm 1999	A case series of 15 patients treated with combination of azathioprine, prednisolone and ursodeoxycholic acid. Follow‐up from 3 to 81 months. A benefit was shown in histopathology and biochemistry.

bid = twice daily